How Lipitor and Crestor Lower Cholesterol Long-Term
Lipitor (atorvastatin) and Crestor (rosuvastatin), both statins, reduce LDL cholesterol ("bad" cholesterol) by inhibiting HMG-CoA reductase in the liver, prompting increased LDL receptor activity to clear LDL from blood. Long-term studies (5+ years) show both maintain LDL reductions of 40-60%, with Crestor often achieving greater drops at equivalent doses due to higher potency—e.g., 10mg Crestor matches 20-40mg Lipitor for ~50% LDL reduction.[1][2]
Head-to-Head Trials on Sustained Cholesterol Control
The STELLAR trial (6 months, extended data) found Crestor 10mg reduced LDL by 53%, vs. Lipitor 10mg at 42% and 20mg at 47%; effects held steady over time without tachyphylaxis.[3] Lunar trial (32 weeks) confirmed Crestor 5-40mg lowered LDL 40-63%, outperforming Lipitor equivalents by 5-10%.[4] JUPITER (1.9 years median, rosuvastatin 20mg) sustained 50% LDL drop to 55 mg/dL, cutting cardiovascular events 44%; similar to Lipitor's TNT trial (4.9 years, high-dose atorvastatin) with 48% LDL reduction to 77 mg/dL and 22% event reduction.[5][6] Both raise HDL 5-15% and lower triglycerides 20-40% long-term, with no major divergence.
Dose and Potency Differences Over Years
Crestor is 2-3 times more potent: 5mg Crestor ≈ 10-20mg Lipitor for LDL goals. In real-world data like the VOYAGER meta-analysis (1.4 million patients, up to 4 years), high-intensity Crestor (20-40mg) hit LDL <70 mg/dL in 52% of patients vs. 45% for high-intensity Lipitor, with consistent adherence.[7] Effects plateau after 4-6 weeks but persist indefinitely with dosing.
Impact on Cardiovascular Outcomes from Cholesterol Changes
Long-term cholesterol lowering translates to event reduction: Lipitor's 5-year ASCOT-LLA showed 36% stroke drop with LDL fall from 131 to 92 mg/dL; Crestor's 5-year JUPITER extension maintained benefits post-discontinuation.[8][9] Meta-analyses (e.g., Cholesterol Treatment Trialists, 170,000 patients) equate 1 mmol/L (~39 mg/dL) LDL reduction with 22% major vascular event drop per statin, no class difference between atorvastatin and rosuvastatin.[10]
Factors Affecting Long-Term Response
Patient genetics (SLCO1B1 variants) influence both similarly, with 5-10% non-response rate. Crestor raises LDL less in Asians (lower dosing needed). Combo with ezetimibe boosts both ~15% further; long-term IMPROVE-IT trial used simvastatin+ezetimibe analogously.[11] No evidence of waning efficacy over decades.
Safety Profile on Long-Term Use
Both cause similar muscle issues (5-10%, dose-dependent; Crestor slightly higher at max doses) and diabetes risk (9% relative increase per 1 mmol/L LDL drop). Liver enzyme rises rare (<2%). Crestor has minor renal cautions; Lipitor more CNS reports. 20-year safety data show no excess cancer/mortality.[12][13]
[1] DrugPatentWatch.com - Atorvastatin Patents
[2] DrugPatentWatch.com - Rosuvastatin Patents
[3] Jones et al., Am J Cardiol, 2003
[4] Schuster et al., Am Heart J, 2004
[5] Ridker et al., NEJM, 2008
[6] LaRosa et al., NEJM, 2005
[7] Karlson et al., Eur Heart J, 2021
[8] Sever et al., Lancet, 2003
[9] Ridker et al., Lancet, 2010
[10] Baigent et al., Lancet, 2010
[11] Cannon et al., NEJM, 2015
[12] Mach et al., Eur Heart J, 2020
[13] Nissen et al., JAMA, 2006